PCM
SPRO icon

Penserra Capital Management’s Spero Therapeutics SPRO Stock Holding History

Penserra Capital Management’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-730
Closed -$13K – 1537
2021
Q3 		$13K Buy
730
+55
+8% +$883 ﹤0.01% 1318
2021
Q2 		$9K Buy
675
+55
+9% +$769 ﹤0.01% 1279
2021
Q1 		$9K Sell
620
-5
-0.8% -$88 ﹤0.01% 1047
2020
Q4 		$12K Buy
+625
New +$9.74K ﹤0.01% 908

Other funds holding SPRO

ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
AVAI
Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Penserra Capital Management's SPRO Position: Q4 2021 in Review

Penserra Capital Management sold out of Spero Therapeutics (SPRO) in Q4 2021, closing a stake of 730 shares — an estimated $13K sold.

Penserra Capital Management first reported a position in SPRO in Q4 2020 and held it in 4 quarters. The position peaked at $13K in Q3 2021. 84 funds tracked by Wall St. Rank hold SPRO as of Q4 2021.

  • Penserra Capital Management reported no remaining Spero Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Penserra Capital Management sold 730 Spero Therapeutics shares in Q4 2021, an estimated $13K.
  • Penserra Capital Management first reported a position in Spero Therapeutics in Q4 2020 and held it in 4 quarters.
  • Penserra Capital Management's Spero Therapeutics position peaked at $13K in Q3 2021.
  • 84 funds tracked by Wall St. Rank held Spero Therapeutics as of Q4 2021.

Based on Penserra Capital Management's 13F filing for Q4 2021, filed 15 Feb 2022.